Razupenem

Synonym(s): SM-216601  |  PZ-601

Class: Beta-lactam (penem)

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Cell wall inhibitor; was in clinical trials for Gram positive infections
Description:	Young CL, Rusca A, Di Stefano AFD, Radicioni M, Binelli D, Loprete L, et al. Safety and multiple dose pharmacokinetics of intravenous PZ-601 (SMP-601): a novel carbapenem. 47th-ICAAC-2007 2007;9-10
Institute where first reported:	Sumitomo Pharmaceuticals (Dainippon Sumitomo Pharma, Japan); Licensed North American rights to Protez Pharmaceuticals, US
Year first mentioned:	2004
Highest developmental phase:	Phase 2
Development status:	Inactive
Reason Dropped:	Adverse effects (S1, 1)

Chemical structure(s):
Canonical SMILES:	C[C@H]1C=C(CN1)C2=CSC(=N2)SC3=C(C(=O)O)N4[C@H]([C@H]3C)[C@@H]([C@@H](C)O)C4=O
Isomeric SMILES:	C[C@H]1C=C(CN1)C2=CSC(=N2)SC3=C(N4[C@H]([C@H]3C)[C@H](C4=O)[C@@H](C)O)C(=O)O
InChI:	InChI=1S/C18H21N3O4S2/c1-7-4-10(5-19-7)11-6-26-18(20-11)27-15-8(2)13-12(9(3)22)16(23)21(13)14(15)17(24)25/h4,6-9,12-13,19,22H,5H2,1-3H3,(H,24,25)/t7-,8+,9+,12+,13+/m0/s1
InChI Key:	XFGOMLIRJYURLQ-GOKYHWASSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/10993211

External links:
Guide to Pharmacology:	razupenem